Speaker Profile
Executive Vice President and Chief Technology Officer, Amgen
Biography
David Reese oversees Amgen's Digital and Technology Innovation, the Office of the Chief Medical Officer, and the development and deployment of artificial intelligence across the enterprise. Reese joined Amgen in 2005 and previously served in various leadership roles within the Research and Development organization. This includes most recently functioning as executive vice president of Research and Development, where he oversaw Amgens worldwide research efforts and the advancement of Amgens pipeline in all therapeutic areas.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
